Related Experiment Videos
Effect of lovastatin on lipoprotein fluidity in patients with hypercholesterolaemia
Insights
Lovastatin treatment significantly reduced cholesterol levels and increased the fluidity of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) in hypercholesterolemic patients, potentially lowering atherosclerosis risk.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Hypercholesterolemia is a major risk factor for atherosclerosis.
- Lipoprotein composition and fluidity influence atherogenesis.
- Statins are primary treatments for hypercholesterolemia.
Purpose of the Study:
- To investigate the effect of lovastatin on plasma lipoprotein fluidity in hypercholesterolemic patients.
- To assess changes in LDL, VLDL, and HDL fluidity following lovastatin therapy.
Main Methods:
- Six hypercholesterolemic patients received lovastatin treatment.
- Plasma lipoproteins (VLDL, LDL, HDL) were analyzed before and after 7 and 12 weeks of treatment.
- Lipoprotein fluidity was measured using fluorescence polarization with DPH probe.
Main Results:
- Lovastatin significantly reduced total cholesterol (-41%), LDL cholesterol (-44%), and VLDL cholesterol (-68%).
- LDL fluidity increased by 11% (7 weeks) and 21% (12 weeks).
- VLDL fluidity increased by 27% after 12 weeks; HDL fluidity remained unchanged.
Conclusions:
- Lovastatin therapy improves LDL and VLDL fluidity in hypercholesterolemic patients.
- These fluidity alterations in atherogenic lipoproteins may reduce atherosclerosis risk.
- Further research is warranted to confirm the clinical significance of these findings.
Abstract:
Lovastatin was administered to six hypercholesterolaemic patients (mean plasma cholesterol 450 mg dl-1). Plasma lipoproteins (VLDL, LDL, and HDL) were separated before and following 7 and 12 weeks treatment with lovastatin. Fluidity was quantified by fluorescence polarization measurements using 1,6-diphenyl 1,3,5 hexatriene (DPH) as the fluorescent probe. Lovastatin treatment resulted in a significant reduction of total plasma cholesterol, LDL cholesterol and VLDL cholesterol (-41%, -44%, -68%, respectively). Fluidity measurements showed significant (p < 0.01) increase in LDL fluidity by 11% and 21% after 7 and 12 weeks of lovastatin treatment, whereas, VLDL fluidity was increased by 27% after 12 weeks of therapy. HDL fluidity was not altered. These alterations in the fluidity of the atherogenic lipoproteins (LDL and VLDL) in hypercholesterolaemic patients may prove to be of significance in reducing the risk of atherosclerosis.